Gulpamuk Gizem, Altinbas Kursat
Department of Psychiatry, Selcuk University, Konya, Turkey.
Psychiatry Clin Psychopharmacol. 2021 Mar 1;31(1):117-119. doi: 10.5152/pcp.2021.20079. eCollection 2021 Mar.
Lithium is a leading therapeutic option for bipolar patients in the treatment of acute and maintenance phases of illness. Lithium levels should be closely monitored due to its narrow therapeutic index. Combination of other treatment regimens with lithium may increase or decrease lithium levels that may cause intoxication symptoms or recurrence of mood episodes. Therefore, clinicians should be aware of the drugs recommended by other medical specialties that may change lithium plasma levels. Nonsteroidal anti-inflammatory drugs, thiazide diuretics, and angiotensin-converting enzyme inhibitors are the best known potential medicines for drug interactions with lithium. In this article, we aimed to present a case report of a patient who was taking lithium for recurrent depression more than 3 years with stable serum levels, but lithium levels decreased fastly after the prescription of ursodeoxycholic acid. The possible mechanism of interaction between lithium and ursodeoxycholic acid was discussed with the current literature.
锂是双相情感障碍患者在疾病急性期和维持期治疗的主要治疗选择。由于其治疗指数较窄,应密切监测锂水平。锂与其他治疗方案联合使用可能会升高或降低锂水平,这可能导致中毒症状或情绪发作复发。因此,临床医生应了解其他医学专科推荐的可能改变锂血浆水平的药物。非甾体抗炎药、噻嗪类利尿剂和血管紧张素转换酶抑制剂是最知名的可能与锂发生药物相互作用的药物。在本文中,我们旨在介绍一例患者的病例报告,该患者服用锂治疗复发性抑郁症超过3年,血清水平稳定,但在开具熊去氧胆酸处方后锂水平迅速下降。结合当前文献讨论了锂与熊去氧胆酸之间可能的相互作用机制。